{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:22:45Z","timestamp":1790043765121,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.bcmd.2013.04.005","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T14:16:51Z","timestamp":1368541011000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study"],"prefix":"10.1016","volume":"51","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2013.04.005_bb0005","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"1995"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0010","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","article-title":"Gaucher's disease: clinical features and natural history","volume":"10","author":"Cox","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","article-title":"Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease","volume":"28","author":"Heitner","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0035","series-title":"Miglustat (Zavesca) Summary of Product Characteristics","author":"Actelion","year":"2010"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007990802576518","article-title":"Goal-oriented therapy with miglustat in Gaucher disease","volume":"25","author":"Pastores","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0045","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0050","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0055","first-page":"703","article-title":"Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease","volume":"91","author":"Giraldo","year":"2006","journal-title":"Haematologica"},{"issue":"Suppl. 3","key":"10.1016\/j.bcmd.2013.04.005_bb0060","first-page":"S200","article-title":"A 2-year, prospective, open-label, non-inferiority study of miglustat as maintenance therapy in adults with type 1 Gaucher disease (GD1) stabilized on enzyme replacement therapy (ERT)","volume":"34","author":"Steiner","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0075","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0080","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0085","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0095","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","article-title":"The clinical course of treated and untreated Gaucher disease. A study of 45 patients","volume":"21","author":"Beutler","year":"1995","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-010-9193-4","article-title":"Dietary modifications in patients receiving miglustat","author":"Champion","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0110","series-title":"Miglustat Package Insert","author":"Actelion","year":"2009"},{"key":"10.1016\/j.bcmd.2013.04.005_bb0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1023\/B:BOLI.0000005623.60471.51","article-title":"A neurological symptom survey of patients with type I Gaucher disease","volume":"26","author":"Pastores","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.2006.00774.x","article-title":"Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?","volume":"115","author":"Halperin","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"\u2018Non-neuronopathic\u2019 Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2013.04.005_bb0130","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:29:14Z","timestamp":1761049754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979613000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1079979613000855"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.04.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}